BIIB - Biogen Inc Stock Analysis
Biogen Inc (BIIB) is a publicly traded company listed on the NASD. It operates in the Drug Manufacturers - General industry, part of the broader Healthcare sector. The company has a market capitalization of 26.47B, generates annual revenue of 9.69B, and reports net income of 1.61B. As of the latest data, the stock is trading at 180.44 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock appears reasonably valued, potentially indicating balanced risk and return. The PEG ratio is below 1, which may indicate the stock is undervalued relative to its growth potential. The company maintains a healthy balance between debt and equity, which is typical for stable businesses. This stock does not currently pay a dividend. This stock tends to be less volatile than the overall market, often preferred by conservative investors.
Analyst recommendation stands at Hold (3.71), indicating current market sentiment. Institutional ownership is reported at 92.19%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of 12.13%, trading within a 52-week range of 110.04 - 185.17.
BIIB - Biogen Inc
180.44
Analyst Consensus
Hold 3.71
BIIB – Analyst Rating Summary
- Strong Buy: 9
- Buy: 12
- Hold: 21
- Sell: 0
- Strong Sell: 0
- Total Analysts: 42
| Index: | NDX, S&P 500 | P/E: | 16.46 | EPS (ttm): | 10.97 | Insider Own: | 0.18% | Shs Outstand: | 146.70M | Perf Week: | 1.50% |
| Market Cap: | 26.47B | Forward P/E: | 11.89 | EPS next Y: | 15.17 | Insider Trans: | -1.03% | Shs Float: | 146.44M | Perf Month: | 15.12% |
| Income(ttm): | 1.61B | PEG: | - | EPS next Q: | 1.76 | Inst Own: | 92.19% | Short Float: | 4.19% | Perf Quarter: | 25.65% |
| Revenue(ttm): | 9.69B | P/S: | 2.73 | EPS this Y: | -9.04% | Inst Trans: | 2.36% | Short Ratio: | 3.43 | Perf Half Y: | 34.51% |
| Book/sh: | 124.11 | P/B: | 1.45 | EPS next Y: | 1.28% | ROA: | 5.59% | Short Interest: | 6.14M | Perf Year: | 12.13% |
| Cash/sh: | 27.00 | P/C: | 6.68 | EPS next 5Y: | -1.57% | ROE: | 9.31% | 52W Range: | 110.04 - 185.17 | Perf YTD: | 18.00% |
| Dividend Est.: | - | P/FCF: | 11.49 | EPS past 3/5Y: | 2.46% -18.66% | ROIC: | 6.49% | 52W High: | 185.17 -2.55% | Beta: | 0.12 |
| Dividend TTM: | - | Quick Ratio: | 2.04 | Sales past 3/5Y: | -3.78% -6.13% | Gross Margin: | 65.99% | 52W Low: | 110.04 63.98% | Perf 5Y: | -24.87% |
| Dividend Ex-Date: | - | Current Ratio: | 2.72 | EPS Y/Y TTM: | -1.03% | Oper. Margin: | 25.17% | RSI (14): | 69.79 | Volatility: | 2.17% 3.02% |
| Employees: | 7605 | Debt/Eq: | 0.36 | Sales Y/Y TTM: | 5.00% | Profit Margin: | 16.60% | Recom: | 2.19 | Target Price: | 180.50 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.36 | EPS Q/Q: | 19.26% | Payout: | 0.00% | Rel Volume: | 0.82 | Prev Close: | 181.30 |
| Sales Surprise: | 8.32% | EPS Surprise: | 23.89% | Sales Q/Q: | 3.33% | Earnings: | Oct 30 BMO | Avg Volume: | 1.79M | Price: | 180.44 |
| SMA20: | 4.31% | SMA50: | 13.65% | SMA200: | 30.14% | Overbought: -0.03% | Volume: | 1,472,767 | Change: | -0.47% | |
Graham Classic formula value: 52.8
(P/E=8 * 1g) Min value: 63.34
(current P/E * 2g) Max value: 131.21
Average value: 82.45
About Biogen Inc
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.